Join us,

SIMPONI indications:

SIMPONI is indicated for the treatment of:¹

Psoriatic Arthritis (PsA)

Active and progressive PsA in adult patients when response to disease-modifying anti-rheumatic drug (DMARD) therapy has been inadequate, when used alone or in combination with methotrexate (MTX).¹

Anklyosing Spondylitis (AS)

Severe, active AS in adults who have responded inadequately to conventional therapy.¹

Ulcerative Colitis (UC)

Moderately to severely active ulcerative colitis (UC) in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6-mercaptopurine (6-MP) or azathioprine (AZA), or who are intolerant to or have medical contraindications for such therapies.¹

Rheumatoid Arthritis (RA)

Moderately to severely active RA in combination with methotrexate, when the response to disease-modifying anti-rheumatic drug (DMARD) therapy including MTX has been inadequate.¹

SIMPONI is also indicated for the treatment of severe, active and progressive RA in adults not previously treated with MTX.

Non-Radiographic Axial Spondyloarthritis (nr-axSpA)

Adults with severe, active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI) evidence, who have had an inadequate response to, or are intolerant to nonsteroidal anti-inflammatory drugs (NSAIDs).¹

RA: Rheumatoid arthritis indication

REMICADE, in combination with methotrexate, is indicated for the reduction of signs and symptoms as well as the improvement in physical function in:

• Adult patients with active disease when the response to disease-modifying antirheumatic drugs (DMARDs), including methotrexate, has been inadequate
• Adult patients with severe, active and progressive disease not previously treated with methotrexate or other DMARDs

PsA: Psoriatic arthritis indication

REMICADE is indicated for treatment of active and progressive psoriatic arthritis in adult patients when the response to previous DMARD therapy has been inadequate.

REMICADE should be administered:

• in combination with methotrexate
• or alone in patients who show intolerance to methotrexate or for whom methotrexate is contraindicated

AS: Ankylosing spondylitis indication

REMICADE is indicated for treatment of severe, active ankylosing spondylitis, in adult patients who have responded inadequately to conventional therapy.

Adult Crohn's disease

REMICADE is indicated for:

• treatment of moderately to severely active Crohn’s disease, in adult patients who have not responded despite a full and adequate course of therapy with a corticosteroid and/or an immunosuppressant; or who are intolerant to or have medical contraindications for such therapies
• treatment of fistulising, active Crohn’s disease, in adult patients who have not responded despite a full and adequate course of therapy with conventional treatment (including antibiotics, drainage and immunosuppressive therapy)

Ulcerative colitis

REMICADE is indicated for treatment of severe, active Crohn’s disease, in children and adolescents aged 6 to 17 years, who have not responded to conventional therapy including a corticosteroid, an immunomodulator and primary nutrition therapy; or who are intolerant to or have contraindications for such therapies. REMICADE has been studied only in combination with conventional immunosuppressive therapy.

Paediatric Crohn's disease

REMICADE is indicated for treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6-mercaptopurine (6-MP) or azathioprine (AZA), or who are intolerant to or have medical contraindications for such therapies.

Paediatric ulcerative colitis

REMICADE is indicated for treatment of severely active ulcerative colitis, in children and adolescents aged 6 to 17 years, who have had an inadequate response to conventional therapy including corticosteroids and 6-MP or AZA, or who are intolerant to or have medical contraindications for such therapies.